Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)
September 23, 2021 11:17 AM EDTUpdated September 24, 02:45 PM
Pharma
FDA+

Fol­low­ing con­tro­ver­sial Aduhelm ap­proval, DC-based neu­rol­o­gy cen­ter bans Bio­gen rep­re­sen­ta­tives from its of­fices — re­port

Nicole DeFeudis

Editor

CEO Michael Vounatsos con­fessed ear­li­er this month that Bio­gen was strug­gling to get its con­tro­ver­sial new Alzheimer’s drug Aduhelm off the ground, with some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times